Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
Novavax shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer for ...
The agreement allows Pfizer to utilize Novavax’s Matrix-M adjuvant in up to two disease areas with its products. Under the terms of the deal, Novavax will receive an upfront payment of $30 million and ...
Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results